TH2-driven manifestations of inborn errors of immunity
- PMID: 38761995
- PMCID: PMC12295673
- DOI: 10.1016/j.jaci.2024.05.007
TH2-driven manifestations of inborn errors of immunity
Abstract
Monogenic lesions in pathways critical for effector functions responsible for immune surveillance, protection against autoinflammation, and appropriate responses to allergens and microorganisms underlie the pathophysiology of inborn errors of immunity (IEI). Variants in cytokine production, cytokine signaling, epithelial barrier function, antigen presentation, receptor signaling, and cellular processes and metabolism can drive autoimmunity, immunodeficiency, and/or allergic inflammation. Identification of these variants has improved our understanding of the role that many of these proteins play in skewing toward TH2-related allergic inflammation. Early-onset or atypical atopic disease, often in conjunction with immunodeficiency and/or autoimmunity, should raise suspicion for an IEI. This becomes a diagnostic dilemma if the initial clinical presentation is solely allergic inflammation, especially when the prevalence of allergic diseases is becoming more common. Genetic sequencing is necessary for IEI diagnosis and is helpful for early recognition and implementation of targeted treatment, if available. Although genetic evaluation is not feasible for all patients with atopy, identifying atopic patients with molecular immune abnormalities may be helpful for diagnostic, therapeutic, and prognostic purposes. In this review, we focus on IEI associated with TH2-driven allergic manifestations and classify them on the basis of the affected molecular pathways and predominant clinical manifestations.
Keywords: Inborn errors of immunity; allergic inflammation; asthma; atopic dermatitis; atopy; dysregulation; eosinophilia; immunomodulation; mast cell dysregulation; primary atopic disorders; primary immunodeficiency.
Published by Elsevier Inc.
Conflict of interest statement
Disclosure statement This work was supported in part by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health. Disclosure of potential conflict of interest: J. D. Milner served on the scientific advisory board for Blueprint Medicine. The rest of the authors declare that they have no relevant conflicts of interest.
Figures

References
-
- Harris NL, Loke P. Recent advances in type-2-cell-mediated immunity: insights from helminth infection. Immunity 2018;48:396. - PubMed
-
- Galli SJ, Gaudenzio N, Tsai M. Mast cells in inflammation and disease: recent progress and ongoing concerns. Annu Rev Immunol 2020;38:49–77. - PubMed
-
- Lyons JJ, Yi T. Mast cell tryptases in allergic inflammation and immediate hyper-sensitivity. Curr Opin Immunol 2021;72:94–106. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources